leadf
logo-loader
viewPreveCeutical Medical Inc.

PreveCeutical Medical names former Johnson & Johnson executive as consultant as it enters commercialization phase

Shetty served as corporate vice president, enterprise supply chain reporting to the CEO and was responsible for the transformation and optimization of J&J's supply chain

PreveCeutical Medical Inc. -
PreveCeutical CEO Van Deventer said the company was very excited and fortunate to have Dr. Shetty work with them

PreveCeutical Medical Inc (CSE:PREV) (OTCQB:PRVCF) (FRA:18H), the health sciences group, has named former executive at multinational giant Johnson & Johnson (NYSE:JNJ) Dr. Ajit Shetty as an advisor and consultant to the company.

"With the company actively working on development, clinical trials, and commercialization of its products, Dr. Shetty's guidance will be very critical in its success," said Stephen Van Deventer, PreveCeutical's chief executive in a brief statement.

READ: PreveCeutical pleased with rodent model of opioid substitute pain-reliever 

"We are very excited and fortunate to have Dr. Shetty work with us."

Illustrious Dr Shetty brings extensive pharmaceutical experience leading commercial and supply chain operations and was 36 years at Johnson & Johnson (J&J) in a wide range of global roles.

"From 2007 to 2012, he served as corporate vice president, enterprise supply chain reporting to the CEO and was responsible for the transformation and optimization of J&J's supply chain. In addition, from 2004 to 2012, he served as chairman of Janssen Pharmaceutic," noted Preveceutical.

He was elected "Manager of the Year 2004" by the magazine Trends, and Kanaal Z and was awarded the Right Honourable Sir and Title of Baron by King Albert II of Belgium in 2008 and the Life-Time Achievement Award by India in 2010.

Shares in Canada were unchanged at C$0.040.

Contact the author at [email protected]

Quick facts: PreveCeutical Medical Inc.

Price: 0.04 CAD

CSE:PREV
Market: CSE
Market Cap: $19.68 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of PreveCeutical Medical Inc. named herein, including the promotion by the Company of PreveCeutical Medical Inc. in any Content on the Site, the...

FOR OUR FULL DISCLAIMER CLICK HERE

PreveCeutical Medical making key advances with its Sol-gel program

Dr Harry Parekh, chief research officer for PreveCeutical Medical Inc (CSE: PREV, OTCQB: PRVCF), tells Proactive's Andrew Scott they've hit a number of key milestones with their Sol-gel program. He says they've now successfully optimised the conditions for extracting cannabinoids from one...

on 10/9/18

2 min read